PAREXEL - Dr. Sy Pretorius Discusses Trends in Adaptive Trials at DIA 2015
This year at DIA I heard many new interesting trends; I’d like to highlight three. I think as an industry we are trying to figure out creative ways to leverage the vast amount of data we have at our disposal. I think a second key trend is sort of putting the patient at the center of the drug development process, so a lot around patient centric drug development, and a third key trend is how do we create more flexibility in what is traditionally a very rigid drug development process. Adaptive clinical trials are important to us as an industry and to our clients because it gives us an opportunity to introduce flexibility into what is traditionally a very rigid drug development and clinical trial process. In other words, it gives us these opportunities during the conduct of a study to reassess, to look at the data and reassess where we are and reassess some of the initial assumptions we made at the outset and revisit these. At PAREXEL, we believe that Adaptive Clinical Trials offer some unique benefits to us as an industry and to our clients, and to this end we’ve been investing primarily in three areas. First and foremost, making sure that we have the statistical expertise and experience to properly design these adaptive trials, secondly, that we have the operational processes and the skills to execute these adaptive trials, and then thirdly, that we have the technology to support and to enable these adaptive trials to be run.